Enterprise Value
7.574B
Cash
77.55M
Avg Qtr Burn
-14.78M
Short % of Float
0.11%
Insider Ownership
0.00%
Institutional Own.
1.04%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REVASCOR® (Rexlemestrocel) Details Heart disease, Hypoplastic Left Heart Syndrome | BLA Acceptance for review | |
RYONCIL™ (Remestemcel-L) Details Acute graft-versus host disease | BLA Resubmission | |
REVASCOR® (Rexlemestrocel) Details Heart disease, Heart failure | BLA FDA meeting | |
Rexlemestrocel Details Chronic lower back pain | Phase 3 Update | |
Remestemcel-L Details Inflammatory bowel disease, Bowel disorder, Crohns disease | Failed Discontinued | |
Failed Discontinued |